Researchers at the University of Augsburg have announced the discovery of a novel biomarker for bladder cancer, potentially revolutionizing diagnostic procedures. The compound, identified as nLc4 and classified as a sugar lipid building block, has been reliably detected in the urine of patients, according to a study released this week.
This discovery holds the promise of enabling bladder cancer diagnosis through simple urine tests, eliminating the need for invasive procedures such as cystoscopies. The research team utilized a highly precise analytical method involving laser-induced fluorescence to visualize sugar structures.
In a study involving over 120 patients, the biomarker, nLc4, not only proved effective in detecting bladder cancer but also demonstrated the capability to provide indications regarding the tumor’s aggressiveness. The findings have been published in the peer-reviewed journal “Cell Reports Medicine”.
“What distinguishes this work is the close integration of biochemical fundamental research with a medically highly relevant question” explained study lead Falk Büttner. “It exemplifies how analytical precision and clinical need can effectively converge”. The team anticipates further research will refine the application of this biomarker in clinical settings.
